Asahi Kasei Pharma Begins Phase III Trial of ART-123 for CIPN
July 3, 2025
Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan for the prevention of chemotherapy-induced peripheral neuropathy related